'Miracle’ weight-loss jabs  leave patients in the dark, study warns

Blockbuster weight-loss jabs hailed as “miracle drugs” are being driven by carefully crafted reporting, financial ties, and hype that leave patients in the dark, new research suggests.

The study, led by Dr Angela Meadows, along with researchers in the US and Australia examines evidence behind GLP-1-based weight-loss drugs.

The researchers reviewed published studies of clinical trials to assess the drugs’ impact, claiming their benefits are often overstated while less favourable results are downplayed or included in supplementary materials – rather than in peer-reviewed published papers.

Dr Meadows, from the Department of Psychology, says positive coverage of the drugs has been widely promoted across major media, trade publications and public debate.

But the study, published in Fat Studies: An Interdisciplinary Journal of Body Weight and Society, suggests messaging is often shaped by pharmaceutical companies and echoed by those with financial ties to manufacturers.

'So-called miracle drugs'

As a result, Dr Meadows has called for more transparency.

She said: “Weight loss is a side effect of these drugs, which were developed to treat diabetes, so the weight-loss formulations are at a much higher dose, significantly increasing the risk of other side effects.

“Many people taking these so-called miracle drugs don’t realise that the side effects are potentially life-changing and may even be fatal.

“How important is it really that you fit into that smaller clothes size? Is it worth your life?”

According to the paper, outcomes vary sharply between individuals, with many patients failing to meet even modest weight-loss targets.

Results tend to plateau after about a year, and the authors claim there is little evidence for long-term maintenance, raising questions about suggestions patients may need to remain on the drugs indefinitely.

Rapid weight regain

The research highlights that stopping treatment can lead to rapid weight regain and reversal of earlier health improvements.

It also challenges how cardiovascular benefits are presented. In one widely reported semaglutide trial, a headline 20 per cent reduction in major heart events reflected relative rather than absolute risk, with the real difference amounting to 1.5 percentage points.

The study also highlights trial authors’ and advocacy groups’ ties to pharmaceutical companies – raising concerns about the role of pharmaceutical funding in research, clinical guidelines and media messaging.

Researchers said the drugs may still have an important role in some metabolic conditions but warned the current narrative risks overstating benefits while downplaying limitations and risks, leaving patients and clinicians without the full picture needed to make informed decisions about whether to use them for weight-loss.

'Very misleading'

Dr Meadows added: “The way these drugs have been promoted to the NHS is very misleading.

“NICE approved Wegovy for people with a BMI over 35 because of the supposed cardiovascular benefits despite the study’s own findings showing no significant benefits in this group.

“But that information wasn’t in the paper. It was on page 35 of 47 of the supplementary materials.

“You really have to dig to find this stuff.”